hENT1 RNA and Protein in Combination May Act as Predictive Biomarkers for Survival for Patients Treated With Adjuvant Gemcitabine in Pancreatic Cancer

被引：0
|
作者：
Hale, J. [1 ]
Evans, A. [1 ]
Aughton, K. [1 ]
Elander, N. O. [1 ,2 ]
Ghaneh, P. [1 ]
Neoptolemos, J. P. [3 ]
Jackson, R. [1 ]
Cox, T. F. [1 ]
Campbell, F. [1 ]
Halloran, C. M. [1 ]
Mackey, J. R. [4 ,5 ]
Scarfe, A. G. [4 ,5 ]
Valle, J. W. [6 ]
Carter, R. [7 ]
Cunningham, D. [8 ,9 ]
Tebbutt, N. C. [10 ]
Goldstein, D. [11 ,12 ]
Shannon, J. [13 ,14 ]
Glimelius, B. [15 ]
Deakin, M. [16 ]
Charnley, R. M. [17 ]
Anthoney, A. [18 ]
Lerch, M. M. [19 ]
Mayerle, J. [19 ,20 ]
Costello, E. [1 ]
Palmer, D. H. [1 ]
Buechler, M. W. [3 ]
Greenhalf, W. [1 ]
机构：
[1] Univ Liverpool, Liverpool Canc Trials Unit, Liverpool, Merseyside, England
[2] Linkoping Univ, Dept Oncol, Linkoping, Sweden
[3] Heidelberg Univ, Dept Surg, Heidelberg, Germany
[4] Cross Canc Inst, Edmonton, AB, Canada
[5] Univ Alberta, Edmonton, AB, Canada
[6] Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England
[7] Glasgow Royal Infirm, Glasgow, Lanark, Scotland
[8] Royal Marsden Natl Hlth Serv NHS Fdn Trust, London, England
[9] Royal Marsden Natl Hlth Serv NHS Fdn Trust, Surrey, England
[10] Austin Hlth, Melbourne, Vic, Australia
[11] Univ New South Wales, Prince Wales Hosp, Sydney, NSW, Australia
[12] Univ New South Wales, Sch Clin, Sydney, NSW, Australia
[13] Nepean Canc Ctr, Kingswood, NSW, Australia
[14] Univ Sydney, Sydney, NSW, Australia
[15] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden
[16] North Staffs Univ Hosp, Stoke On Trent, Staffs, England
[17] Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England
[18] St James Univ Hosp, Leeds, W Yorkshire, England
[19] Univ Med Greifswald, Dept Med A, Greifswald, Germany
[20] Klinikum LMU Munchen Grosshadern, Med Klin & Poliklin 2, Munich, Germany
来源：
PANCREAS | 2019年 / 48卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1436 / 1437
页数：2
相关论文
共 50 条
  • [21] Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma HENT1 positive: back to the future
    Calegari, M. A.
    Orlandi, A.
    Cocomazzi, A.
    Martini, M.
    Bagala, C.
    Indellicati, G.
    Zurlo, V.
    Monterisi, S.
    Di Dio, C.
    Barile, R.
    Di Salvatore, M. A.
    Basso, M.
    Cassano, A.
    Larocca, L. M.
    Barone, C.
    ANNALS OF ONCOLOGY, 2015, 26
  • [22] hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
    Aughton, Karen
    Elander, Nils O.
    Evans, Anthony
    Jackson, Richard
    Campbell, Fiona
    Costello, Eithne
    Halloran, Christopher M.
    Mackey, John R.
    Scarfe, Andrew G.
    Valle, Juan W.
    Carter, Ross
    Cunningham, David
    Tebbutt, Niall C.
    Goldstein, David
    Shannon, Jennifer
    Glimelius, Bengt
    Hackert, Thilo
    Charnley, Richard M.
    Anthoney, Alan
    Lerch, Markus M.
    Mayerle, Julia
    Palmer, Daniel H.
    Buechler, Markus W.
    Ghaneh, Paula
    Neoptolemos, John P.
    Greenhalf, William
    CANCERS, 2021, 13 (22)
  • [23] Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy
    Bird, N. T. E.
    Elmasry, M.
    Jones, R.
    Psarelli, E.
    Dodd, J.
    Malik, H.
    Greenhalf, W.
    Kitteringham, N.
    Ghaneh, P.
    Neoptolemos, J. P.
    Palmer, D.
    BRITISH JOURNAL OF SURGERY, 2017, 104 (04) : 328 - 336
  • [24] Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer
    Kim, Jaihwan
    Kim, Haeryoung
    Lee, Jong-Chan
    Kim, Jin Won
    Paik, Woo Hyun
    Lee, Sang Hyub
    Hwang, Jin-Hyeok
    Ryu, Ji Kon
    Kim, Yong-Tae
    PLOS ONE, 2018, 13 (12):
  • [25] A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine
    Kalloger, Steve E.
    Riazy, Maziar
    Tessier-Cloutier, Basile
    Karasinska, Joanna M.
    Gao, Dongxia
    Peixoto, Renata D.
    Samimi, Setareh
    Chow, Christine
    Wong, Hui-Li
    Mackey, John R.
    Renouf, Daniel J.
    Schaeffer, David F.
    JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2017, 3 (03): : 179 - 190
  • [26] hENT1 gene expression as a predictor of response to gemcitabine and nab-paclitaxel in advanced pancreatic cancer.
    Perera, Sheron
    Jang, Gun Ho
    Zhang, Amy
    Denroche, Robert Edward
    Dodd, Anna
    Ramotar, Stephanie
    Hutchinson, Shawn
    Wang, Yifan
    Tehfe, Mustapha
    Ramjeesingh, Ravi
    Biagi, James Joseph
    Lam, Bernard
    Wilson, Julie
    Notta, Faiyaz
    Fischer, Sandra
    Zogopoulos, George
    Gallinger, Steven
    Grant, Robert C.
    Knox, Jennifer J.
    O'Kane, Grainne M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
    Guo, Zhongyi
    Wang, Feng
    Di, Yang
    Yao, Lie
    Yu, Xinzhe
    Fu, Deliang
    Li, Ji
    Jin, Chen
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2018, 13 : 4869 - 4880
  • [28] Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma
    Borbath, I.
    Verbrugghe, L.
    Lai, R.
    Gigot, J. F.
    Humblet, Y.
    Piessevaux, H.
    Sempoux, C.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (07) : 990 - 996
  • [29] Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer
    Xi, Yue
    Li, Ting
    Xi, Yun
    Zeng, Xinyi
    Miao, Ying
    Guo, Rui
    Zhang, Min
    Li, Biao
    CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [30] Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer
    Yue Xi
    Ting Li
    Yun Xi
    Xinyi Zeng
    Ying Miao
    Rui Guo
    Min Zhang
    Biao Li
    Cancer Cell International, 22
12345